Aurobindo Pharma Ltd is pleased to announce that its joint venture, Cephazone Pharma LLC, at California, USA, a facility dedicated to cephalosporin injectable drugs, has received the first ANDA approval for Ceftriaxone
The company has received approval for Ceftriaxone injectable, a third generation cephalosporin antibiotic. 250mg, 500mg, 1Gm and 2Gm single use vials for intra muscular, intra venous use and also 1Gm and 2Gm bottles (popularly known as piggy pack) for intra venous use are approved. Ceftriaxone is the research innovation of Hoffmann-La Roche and often used in respiratory infections and as a choice antibiotic in bacterial meningitis.
Besides its use is well documented in pediatrics in febrile conditions to prevent possible septicemias.
Cephazone is a joint venture of Aurobindo and has filed several ANDAs with USFDA. Aurobindo has already received the facility approval for sterile Cephalosporin APIs.
Cephalosporin injectables market is an attractive opportunity in USA and globally. Aurobindo is vertically integrated in the cephalosporin category and enjoys a leading position in the category.
